Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-08-31

Study Completion Date

2016-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

\[Changes to the protocol made until the stage of the statistical analysis plan, before data analysis and also before unblinding.\]

1. Objective

1.1 Main Objective

We aim to determine, through mean INR difference between formulations, whether there is therapeutic equivalency between the branded warfarin sodium (Marevan®) and the generic formulations in atrial fibrillation patients in Brazil.

1.2 Specific Objective

In order to achieve the objective, we aim to assess with each warfarin formulation :
* Delta INR \[new primary outcome\];
* mean INR \[mean prothrombin time will not be analyzed since it will convey the same information as the mean INR\];
* mean dosage needed for anticoagulation \[new outcome\];
* clinical events (the frequency of thromboembolic events, bleedings, deaths and adverse events);
* the time in therapeutic range;
* and compliance with treatment.
2. Hypothesis

Our hypothesis is that the delta INR of patients when using the generic tablets of warfarin sodium does not differ by more than 0.49 (two-sided) from the mean INR obtained when using the branded formulation, thereby demonstrating therapeutic equivalence. We will also assess this same outcome to assess therapeutic equivalence between the generic formulations to each other.
3. Type of Study

This study is a crossover randomized controlled equivalence trial. It comprises four phases, each one one-month long, being the first one a run-in period. Patients will use a different warfarin sodium tablet formulation in each one of the phases 2, 3 and 4: either the branded Marevan® (União Química/Farmoquímica, Brasil), or two generic drugs, (manufactured by União Química Farmacêutica Nacional S/A or Laboratório Teuto Brasileiro S/A, Brasil) purchased from Brazilian drugstores (not directly from the manufacturer). Every patient will use each one of the three formulations in a previously determined sequence (A, B, C, D, E or F) to which he was assigned by randomization.

Since patients included in the study will already be using warfarin and it is not ethically acceptable to interrupt this treatment, we planned a run-in period equivalent to seven warfarin half-lives, long enough to washout any previous warfarin treatment. Then, in this first phase, patients will start treatment with the same warfarin formulation that will be used in the second phase thus avoiding the carry-over effect. This period will also be used to select patients compliant with treatment, accepting those that during the run-in have at least one of the three (including the baseline) INR results within 2.0 and 3.0 and a difference of INR results at the 3th and 4th week ≤ ±0.8.
4. Methods

An independent investigator (initials TFCP) will use a computer random number generator to allocate patients to one of the six sequences of treatment \[update: we opted to apply randomization through numbered, opaque, sealed envelopes in order to facilitate allocation concealment\]. The principal investigator (initials CGF) will separate, repack and dispense drugs for patients in opaque drug containers of identical appearance \[update: the step of repacking the drugs in opaque containers was made by two investigators external to the study, BR and MFST, instead of the principal investigator\]. This process will be based on the initials of the patient and the alphanumeric code, maintaining the allocation concealment since TFCP will be responsible for assigning to the repacked drugs the patient initials and the alphanumeric code correlated with the formulation of warfarin utilized. TFCP will also be accountable to conceal the allocation until the statistical analysis at the end of the study \[update: BR and MFST created the coding and maintained its concealment\]. Due to the features of the drug containers, physicians and the principal investigator (that assess patients and collect outcomes) will be blinded. Patients may not be blinded depending on the appearance of the manufactured tablets, but the main outcome will be a laboratory result (INR).
5. Sample Size

Forty-eight patients (eight in each group) is the minimum necessary number of individuals to detect a clinically significant fluctuation of 0.49 in the mean INR, with a 90% power at a 5% level of significance, if one were present. This sample size was estimated considering the Pocock's statistical method for quantitative outcomes and an achieved mean INR and standard deviation with the branded warfarin of 2.45 and 0.29 respectively \[update: later we considered a more conservative standard deviation of 0.34, which resulted in a sample size of 11 patients per group\]. To compensate possible withdrawals or exclusions of patients we plan to recruit 60 patients.
6. Statistical Analysis

For the INR, PT and TTR outcomes paired t-test will be used at a two-sided 5% level of significance. These analysis will be per protocol, i.e., data from patients that during the follow-up start treatment with substances or drugs that interact either in a moderate or major way or are contraindicated when used with warfarin (Annex I) will be excluded \[update: multiple t-tests would not be adequate because nominal significance levels would not reflect the actual alfa, and thus we decided to apply multilevel mixed-effects linear regression. We have new definitions for per protocol analyses.\].

Binary outcomes (thromboembolic or bleeding events) will be analysed by Mcnemar test at a 5% level of significance using intention to treat i.e. considering missing data as adverse outcomes. In this case sensibility analysis will be conducted \[update: we decided for just presenting the events recorded during the trial without any hypothesis testing due to cross-over design limitations and lower power for these outcomes\]. Exploratory analysis for subgroup of patients are not intended.
7. Annex I (obtained from the online database Micromedex ® 2.0 in September 13, 2013)

* abciximab
* acarbose
* acemetacin
* acenocoumarol
* acetaminophen
* agrimony
* alclofenac
* alefacept
* allopurinol
* aloe
* aminoglutethimide
* amiodarone
* amitriptyline
* amobarbital sodium
* amoxapine
* amoxicillin
* ampicillin trihydrate
* amprenavir
* angelica
* anise
* antithyroid agents
* apazone
* apixaban
* aprepitant
* aprobarbital
* argatroban
* armodafinil
* arnica
* asafetida
* aspirin
* astragalus
* atazanavir
* atenolol
* atovaquone
* avocado
* azathioprine
* azithromycin
* bee pollen
* benoxaprofen
* benzbromarone
* betamethasone
* bicalutamide
* bilberry
* bismuth subsalicylate
* bivalirudin
* black cohosh extract
* black currant
* black haw
* black tea
* bladderwrack
* boceprevir
* bogbean
* boldo
* borage
* bosentan
* bromelain
* bromfenac
* buchu
* bufexamac
* butabarbital
* butalbital
* capecitabine
* capsaicin
* carbamazepine
* carbenicillin disodium
* carboplatin
* carprofen
* cassia
* cat's claw
* cefadroxil
* cefamandole
* cefazolin sodium
* cefdinir
* cefepime
* cefixime
* cefoperazone
* cefotaxime
* cefotetan
* cefpodoxime
* ceftazidime
* ceftibuten
* ceftizoxime
* ceftriaxone
* celecoxib
* celery
* cephalexin
* cephalothin sodium
* cephapirin
* chamomile
* chaparral
* chitosan
* chloral hydrate
* chloramphenicol
* chlordiazepoxide
* chlorotrianisene
* chlorpromazine hydrochloride
* cholestyramine
* chondroitin
* cimetidine
* cinchona
* ciprofloxacin
* cisapride monohydrate
* cisplatin
* citalopram
* clarithromycin
* clofibrate
* clomipramine hydrochloride
* clopidogrel
* clove
* clove oil
* cloxacillin benzathine
* coenzyme Q10
* colesevelam
* contraceptives, combination
* cortisone
* cranberry juice
* curcumin
* cyclophosphamide
* cyclosporine, modified
* dabigatran
* dabrafenib
* dalteparin
* danaparoid
* danazol
* dandelion
* dapsone
* darunavir
* deferasirox
* delavirdine
* demeclocycline
* desipramine
* desvenlafaxine
* devil's claw
* dexamethasone
* dexlansoprazole
* dexmethylphenidate
* diazoxide
* diclofenac
* dicloxacillin
* diethylstilbestrol
* diflunisal
* dipyridamole
* dipyrone
* disopyramide
* disulfiram
* dong quai
* dothiepin
* doxepin
* doxorubicin
* doxycycline calcium
* dronedarone
* droxicam
* duloxetine
* enoxacin
* enoxaparin
* enteral nutrition
* enzalutamide
* eptifibatide
* erlotinib
* erythromycin acistrate
* escitalopram
* esomeprazole
* eterobarb
* ethacrynic acid
* ethanol
* ethchlorvynol
* ethotoin
* etodolac
* etoposide
* etravirine
* etretinate
* evening primrose oil
* exenatide
* ezetimibe
* felbamate
* fenbufen
* fenofibrate
* fenofibric acid
* fenoprofen
* fenugreek
* feverfew
* fish oil
* floctafenine
* flosequinan
* fluconazole
* fludrocortisone acetate
* flufenamic acid
* fluorouracil
* fluoxetine
* fluoxymesterone
* flurbiprofen
* flutamide
* fluvastatin
* fluvoxamine
* fosamprenavir
* fosaprepitant
* garlic
* gatifloxacin
* gefitinib
* gemcitabine
* gemfibrozil
* gemifloxacin
* ginger
* ginkgo
* ginseng, siberian
* glimepiride
* glipizide
* glucagon
* glucosamine
* glutethimide
* glyburide
* goldenseal
* green tea
* griseofulvin
* guggul
* halothane
* heparin calcium
* heptabarbital
* hexobarbital sodium
* high protein food
* horse chestnut
* horseradish
* hydrocortisone
* ibritumomab
* ibuprofen
* ifosfamide
* imatinib
* imipramine hydrochloride
* indomethacin
* indoprofen
* infliximab
* influenza virus vaccine
* ipriflavone
* isoniazid
* isoxicam
* itraconazole
* ivacaftor
* ivermectin
* kava
* ketoconazole
* ketoprofen
* ketorolac tromethamine
* lactulose
* lansoprazole
* leflunomide
* lepirudin
* levamisole
* levofloxacin
* licorice
* lopinavir
* lornoxicam
* lovastatin
* lycium
* marijuana
* meadowsweet
* mechlorethamine
* meclofenamate
* mefenamic acid
* melatonin
* meloxicam
* menthol
* mephobarbital
* mercaptopurine
* mesalamine
* mesna
* methandrostenolone
* methicillin
* methotrexate
* methyl salicylate
* methylphenidate
* methylprednisolone acetate
* methyltestosterone
* metronidazole
* miconazole
* mifepristone
* milnacipran
* minocycline hydrochloride
* mistletoe
* mitotane
* moricizine hydrochloride
* motherwort
* moxalactam
* moxifloxacin
* nabumetone
* nafcillin
* nalidixic acid
* nandrolone
* naproxen
* nelfinavir
* neomycin
* nettle extract
* nevirapine
* niacin
* nilutamide
* nimesulide
* norfloxacin
* nortriptyline hydrochloride
* noscapine
* ofloxacin
* omega-3-acid ethyl esters
* omeprazole
* onion oil
* orlistat
* oseltamivir
* oxacillin
* oxandrolone
* oxaprozin
* oxymetholone
* oxyphenbutazone
* oxytetracycline
* pantoprazole
* papaya
* paramethasone
* paroxetine
* parsley
* passionflower
* pau d'arco
* penicillin G
* penicillin V benzathine
* pentosan polysulfate sodium
* pentoxifylline
* phenindione
* phenobarbital
* phenprocoumon
* phenylbutazone
* phenytoin
* phytonadione
* piperacillin
* piracetam
* pirazolac
* piroxicam
* pirprofen
* policosanol
* pomegranate
* poplar
* posaconazole
* prasugrel
* prednisolone
* prednisone
* prickly ash
* primidone
* procarbazine
* proguanil
* propafenone hydrochloride
* propoxyphene
* propranolol
* propyphenazone
* proquazone
* protriptyline
* pumpkin seed
* quassia
* quetiapine
* quinestrol
* quinidine
* quinine
* rabeprazole sodium
* raloxifene
* ranitidine
* red clover
* rifabutin
* rifampin
* rifapentine
* rifaximin
* rilonacept
* ritonavir
* rivaroxaban
* rofecoxib
* romidepsin
* ropinirole
* rosuvastatin
* roxithromycin
* salicylates
* saquinavir
* sarsaparilla
* saw palmetto extract
* secobarbital
* senega
* sertraline
* simvastatin
* sitaxsentan
* skullcap
* sorafenib
* soybean
* spironolactone
* st john's wort
* stanozolol
* sucralfate
* sulfamethoxazole
* sulfasalazine
* sulfinpyrazone
* sulfisoxazole
* sulindac
* sulofenur
* suprofen
* sweet woodruff
* tamarind
* tamoxifen
* tan shen
* teduglutide
* telaprevir
* telithromycin
* tenidap sodium
* tenoxicam
* terbinafine
* teriflunomide
* testosterone
* tetracycline
* thyroid hormones
* tiaprofenic acid
* tibolone
* ticarcillin
* ticlopidine
* tigecycline
* tinidazole
* tinzaparin
* tirofiban
* tocilizumab
* tolmetin
* tolterodine tartrate
* tonka
* toremifene citrate
* torsemide
* tramadol
* trastuzumab
* treprostinil
* triamcinolone acetonide
* trimipramine
* valdecoxib
* valproic acid
* vancomycin
* vemurafenib
* venlafaxine
* vilazodone
* vincristine
* vindesine
* vitamin A
* vitamin E
* vitamin K
* voriconazole
* vorinostat
* wild lettuce
* willow
* wintergreen
* yarrow
* zafirlukast
* zileuton
* zomepirac sodium
* zotepine

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Therapeutic Equivalency Warfarin Drugs, Generic Anticoagulants Anticoagulants [Pharmacological Action] Coumarins

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Caregivers Investigators Outcome Assessors

Intervention Type DRUG

Generic warfarin sodium tablets, manufacturer (Laboratório Teuto Brasileiro S/A, Brazil), by mouth; dose adjusted according to INR and medical judgement.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Marevan®

Branded warfarin sodium tablets (manufacturer União Química Farmacêutica Nacional S/A, Brazil) by mouth; dose adjusted according to INR and medical judgement.

Intervention Type DRUG

generic warfarin #1

Generic warfarin sodium tablets, manufacturer (União Química Farmacêutica Nacional S/A, Brazil), by mouth; dose adjusted according to INR and medical judgement.

Intervention Type DRUG

generic warfarin #2

Generic warfarin sodium tablets, manufacturer (Laboratório Teuto Brasileiro S/A, Brazil), by mouth; dose adjusted according to INR and medical judgement.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

warfarin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* diagnosis of nonvalvular atrial fibrillation atrial flutter by electrocardiogram and echocardiography;
* CHA2DS2VASc score equal to or greater than 1;
* already in use of warfarin for at least 2 months;
* during the run-in, at least one of the three (including the baseline) INR results within 2.0 and 3.0 and a difference of INR results at the 3th and 4th week ≤ ±0.8
* signing of Informed Consent Form.

Exclusion Criteria

* patients with serious contraindications to the use of anticoagulants (significant bleeding, known sensitivity to warfarin);
* women of childbearing age, pregnant or breastfeeding;
* patients with thrombocytopenia;
* patients with hepatic or renal impairment;
* patients with a history of bleeding episodes due to congenital deficiency of coagulation factors;
* patients enrolled in another trial;
* patients initiating treatment with drugs with major interactions or which are contraindicated when used concomitantly with warfarin, according to our list (Annex I).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Carolina Gomes Freitas

Graduate student (PhD)

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Carolina Gomes Freitas, BPharm

Role: PRINCIPAL_INVESTIGATOR

Federal University of Sao Paulo (UNIFESP)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital São Paulo/Hospital Universitário da UNIFESP (University Hospital of UNIFESP)

São Paulo, São Paulo, Brazil

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Brazil

References

Explore related publications, articles, or registry entries linked to this study.

Gomes Freitas C, Walsh M, Coutinho EL, Vincenzo de Paola AA, Atallah AN. Examining therapeutic equivalence between branded and generic warfarin in Brazil: The WARFA crossover randomized controlled trial. PLoS One. 2021 Apr 1;16(4):e0248567. doi: 10.1371/journal.pone.0248567. eCollection 2021.

Reference Type DERIVED

PMID: 33793580 (View on PubMed)

Freitas CG, Walsh M, Atallah AN. Design and rationale for the WARFA trial: a randomized controlled cross-over trial testing the therapeutic equivalence of branded and generic warfarin in atrial fibrillation patients in Brazil. BMC Cardiovasc Disord. 2017 Jun 7;17(1):148. doi: 10.1186/s12872-017-0584-4.

Reference Type DERIVED

PMID: 28592234 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

U1111-1155-4833

Identifier Type: REGISTRY

Identifier Source: secondary_id

RCT 01 GW

Identifier Type: -

Identifier Source: org_study_id

Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil

Study Results

Basic Information

Brief Summary

Detailed Description

Conditions

Keywords

Study Design

Study Groups

Sequence A

Marevan®

generic warfarin #1

generic warfarin #2

Sequence B

Marevan®

generic warfarin #1

generic warfarin #2

Sequence C

Marevan®

generic warfarin #1

generic warfarin #2

Sequence D

Marevan®

generic warfarin #1

generic warfarin #2

Sequence E

Marevan®

generic warfarin #1

generic warfarin #2

Sequence F

Marevan®

generic warfarin #1

generic warfarin #2

Interventions

Marevan®

generic warfarin #1

generic warfarin #2

Other Intervention Names

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Sponsors

Fundação de Amparo à Pesquisa do Estado de São Paulo

Federal University of São Paulo

Responsible Party

Carolina Gomes Freitas

Principal Investigators

Carolina Gomes Freitas, BPharm

Locations

Hospital São Paulo/Hospital Universitário da UNIFESP (University Hospital of UNIFESP)

Countries

References

Gomes Freitas C, Walsh M, Coutinho EL, Vincenzo de Paola AA, Atallah AN. Examining therapeutic equivalence between branded and generic warfarin in Brazil: The WARFA crossover randomized controlled trial. PLoS One. 2021 Apr 1;16(4):e0248567. doi: 10.1371/journal.pone.0248567. eCollection 2021.

Other Identifiers

U1111-1155-4833

RCT 01 GW